Adaptimmune Ltd.
57c Milton Park
Abingdon
Oxfordshire
OX14 4RX
United Kingdom
Tel: +44-(0)-1235-438-642
Fax: +44-(0)-1235-438-607
Website: http://www.adaptimmune.com/
132 articles about Adaptimmune Ltd.
-
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
7/22/2020
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below). The press release and the live webcast of the con
-
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares - June 04, 2020
6/4/2020
PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”). Adaptimmune sold a total of 23,575,000 ADSs at a price to the public of $11.00 per ADS, including 3,075,000 ADSs pursuant to the exercise in full by the underwriters of their option to p
-
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares - June 02, 2020
6/2/2020
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares at a price to the public of $11.00 per ADS.
-
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares - Jun 01, 2020
6/1/2020
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that it intends to offer and sell 12,500,000 American Depositary Shares in an underwritten public offering.
-
Adaptimmune Reports Q1 Financial Results
5/14/2020
- Upfront payment of $50m received from Astellas and approximately $90m offering completed - - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug Designation positive opinion for ADP-A2M4 in the EU adds to US FDA ODD and RMAT designations - - Upcoming presentations at major scientific meetings with data from ADP-A2M4, ADP-A2AFP, and allogeneic programs - - Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) - PHILADELPHIA and OXFORDSHIRE, United Kin
-
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
5/12/2020
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, presented advances from its “off-the-shelf” or allogeneic platform at the American Society for Gene and Cell Therapy Annual meeting which kicked off in virtual format.
-
BioSpace Global Roundup, April 30
4/30/2020
Biopharma companies from across the globe provide updates on their business and pipelines. -
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020
4/29/2020
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for Q1 2020, before the U.S. markets open on Thursday, May 14, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below). The pres
-
Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products
4/28/2020
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s Committee for Orphan Medicinal Products has adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas.
-
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
2/27/2020
- Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 -
-
Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020
2/20/2020
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report financial results for the Full Year / Fourth Quarter 2019 and provide a business update, before the U.S. markets open on Thursday, February 27, 2020.
-
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
2/7/2020
PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American Depositary Shares (“ADSs”), which initially closed on January 24, 2020, have exercised in full their option to purchase an additional 3,150,000 of its ADSs at a price to the public of $4.00 per ADS, raising a
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
1/24/2020
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, announced the closing of its previously announced underwritten public offering of its American Depositary Shares.
-
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
1/21/2020
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, announced that it intends to offer and sell American Depositary Shares in an underwritten public offering.
-
Clinical Catch-Up: January 13-17
1/20/2020
There were plenty of clinical trial announcements this week. Here's a look. -
BioSpace Movers & Shakers, Jan. 17
1/17/2020
Pharma companies add new members to executive ranks and boards of directors. -
With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.
-
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
1/14/2020
Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products
-
Helen Tayton-Martin, Adaptimmune’s chief business officer and co-founder, said the partnership with Astellas builds upon and extends an existing collaboration focused on gene editing of iPSC cells.